Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 31, 2023

SELL
$2.03 - $4.28 $36,357 - $76,654
-17,910 Reduced 37.57%
29,760 $67,000
Q2 2022

Jul 26, 2022

BUY
$3.17 - $6.17 $94,370 - $183,680
29,770 Added 166.31%
47,670 $181,000
Q1 2022

Apr 11, 2022

BUY
$4.16 - $13.72 $74,464 - $245,588
17,900 New
17,900 $96,000
Q1 2018

Apr 30, 2018

SELL
$57.4 - $108.44 $582,610 - $1.1 Million
-10,150 Closed
0 $0
Q3 2017

Oct 31, 2017

BUY
$17.79 - $24.0 $180,568 - $243,600
10,150
10,150 $244,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $154M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Everence Capital Management Inc Portfolio

Follow Everence Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Everence Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Everence Capital Management Inc with notifications on news.